Evidence map›Paper›PMID 42151856›Full record

ArticleBMC neurology2026

Early neurodevelopmental outcomes in a child with tuberous sclerosis complex treated with everolimus and vigabatrin.

Sarah Ml Wilson, Megan Samuels, Luana Pimentel, Shelley Varnado, Claire Sartwell, Rosleen Mansour, Deborah Pearson, Hope Northrup, Mary Kay Koenig

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sarah Ml WilsonDepartment of Pediatrics, Division of Child and Adolescent Neurology, The University of Texas Health Science Center at Houston, 6410 Fannin Street, Houston, TX, 77030, United States. Sarah.m.lund@uth.tmc.edu.
Megan SamuelsDepartment of Pediatrics, Division of Medical Genetics, The University of Texas Health Science Center at Houston,, Houston, TX, United States.
Luana PimentelDepartment of Pediatrics, Division of Child and Adolescent Neurology, The University of Texas Health Science Center at Houston, 6410 Fannin Street, Houston, TX, 77030, United States.
Shelley VarnadoDepartment of Pediatrics, Division of Child and Adolescent Neurology, The University of Texas Health Science Center at Houston, 6410 Fannin Street, Houston, TX, 77030, United States.
Claire SartwellDepartment of Pediatrics, Division of Medical Genetics, The University of Texas Health Science Center at Houston,, Houston, TX, United States.
Rosleen MansourDepartment of Psychiatry, Division of Child and Adolescent Psychiatry, The University of Texas Health Science Center at Houston, Houston, TX, United States.
Deborah PearsonDepartment of Psychiatry, Division of Child and Adolescent Psychiatry, The University of Texas Health Science Center at Houston, Houston, TX, United States.
Hope NorthrupDepartment of Pediatrics, Division of Medical Genetics, The University of Texas Health Science Center at Houston,, Houston, TX, United States.
Mary Kay KoenigDepartment of Pediatrics, Division of Child and Adolescent Neurology, The University of Texas Health Science Center at Houston, 6410 Fannin Street, Houston, TX, 77030, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo report early neurodevelopmental outcomes in a child with Tuberous Sclerosis Complex (TSC) treated with everolimus and vigabatrin.

methodsThe authors report a five-year-old girl with Tuberous Sclerosis Complex who was initiated on vigabatrin at seven weeks old to treat infantile spasms and on everolimus at two months of age to treat a subependymal giant cell astrocytoma. Neuropsychological assessments were conducted in this patient at 12, 24, and 36 months using the Bayley-III and Vineland-II.

resultsOn the Bayley-III, the patient had a high average cognitive composite score at 12 months and a high average language composite score at 36 months. Bayley-III assessments at 12, 24, and 36 months, yielded average cognitive, language, and motor composite scores. On the Vineland-II at 12 months, her standard score fell in the moderately low range on daily living skills and overall adaptive behavior. Vineland-II assessments at 12, 24, and 36 months yielded average range standard scores in the areas of communication, socialization, daily living skills, overall adaptive behavior, and motor skills. DISCUSSION: This case highlights early neurodevelopmental outcomes in one TSC child treated with everolimus and vigabatrin in infancy. Continued assessment and longitudinal follow-up is required to understand the broader implications of early treatment with mTOR inhibitors and vigabatrin in TSC patients in childhood.

Indexed as

AnticonvulsantsEverolimusNeurodevelopmental DisordersTuberous SclerosisVigabatrinChild, PreschoolFemaleHumansNeuropsychological TestsTreatment OutcomeAnticonvulsantsEverolimusVigabatrinBayley-IIIEverolimusmTOR inhibitorNeurodevelopmentNeuropsychological TestingTuberous Sclerosis Complex (TSC)VigabatrinVineland-II

Identifiers

PMID42151856
PMCPMC13347987

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.